

GENETRONICS BIOMEDICAL CORP  
Form 8-K  
September 16, 2004

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 13, 2004

Genetronics Biomedical Corporation

(Exact name of registrant as specified in its charter)

Delaware

0-29608

33-0969592

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

11199 Sorrento Valley Road, San Diego, CA

92121-1334

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

(858) 597-6006

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Top of the Form**

**Item 8.01. Other Events.**

Effective at 6:30 am PST on September 13, 2004, we implemented a one-for-four reverse stock split of our common stock. The reverse stock split did not change the number of authorized shares of common stock we may issue. The one-for-four reverse stock split was approved by our board of directors and subsequently approved by the registrant's stockholders at a special meeting. The number of shares voting in favor of the reverse split was sufficient for approval.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

See Exhibit Index below.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Genetronics Biomedical Corporation  
(Registrant)

*September 16, 2004*

By: *Peter Kies*

---

*Name: Peter Kies*  
*Title: Chief Financial Officer*

---

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation as filed with the Delaware Secretary of State on September 10, 2004.
EX-99.1	Press Release dated September 13, 2004.